Komrokji R, al Ali N, Chan O, Sweet K, Kuykendall A, Lancet J, Padron E, Sallman DA. IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy. haematol [Internet]. 2023Apr.1 [cited 2026Apr.1];108(4):1168-72. Available from: https://haematologica.org/article/view/haematol.2022.281607